Since the arrival of the coronavirus, lupus and the most prescribed drug used to treat it – hydroxychloroquine – have been thrust into the spotlight despite the mounting scientific evidence that the drug does not seem to improve clinical outcomes in patients with COVID-19. Talked about less is the impact and burden of COVID-19 on people with lupus.
What parallels exist in the overreactive immune response seen in lupus and COVID-19?
Are people with lupus more or less at risk for COVID-19?
Are medications used by people with lupus more or less effective in COVID-19?
Diving deep on research on behalf of the lupus community during this crisis, the Lupus Research Alliance (LRA) and Lupus Therapeutics (an affiliate of the LRA) discuss with a panel of experts actions taken to better understand these and other questions.
Moderator:
Teo Staeva, PhD, LRA Chief Scientific Officer
Panelists:
Gary Koretzky, MD, PhD, Professor of Medicine, Weill Cornell Medicine, and Chair, LRA Scientific Advisory Board
Roberto Caricchio, MD, Professor of Medicine, Chief of Rheumatology, Lupus Program Director at Temple University and LRA-funded investigator
Milena Gianfrancesco, PhD, MPH, Assistant Professor of Medicine, UCSF
Amr H. Sawalha, MD, Chief of the Division of Pediatric Rheumatology, University of Pittsburgh and LRA-funded investigator
Albert Roy, Executive Director, Lupus Therapeutics
Learn more:
Lupus affects millions worldwide, and there is no cure. Please help the Lupus Research Alliance to raise awareness and funds for lupus research.
Follow Us:
